Novel naphthyl and isoquinoline sulfonamide derivatives

Compounds of formula I

• wherein,
• R1 is selected from cyanoalkyl, haloalkoxy, haloalkyl, cyclopropyl and oxetanyl;
• R2 is selected from alkoxy, H or halo;
• X1 is N and X2 is CR4 and X3 is N, or
• X1 is CR3, X2 is CR4, and X3 is N or CR5, or
• X1 is CR3, X2 is N, and X3 is CR5;
• R3 is selected from alkoxy, H, halo, haloalkoxy;
• R4 is selected from alkoxy, H, halo;
• R5 is selected from H, halo;
• W is selected from Ring A, Ring B, or Ring C
• Y1 is CR6, Y2 is CR7, Y3 is CR8 and Y4 is CR9, or
• Y1 is N, Y2 is CR7, Y3 is CR8 and Y4 is CR9, or
• Y1 is N, Y2 is CR7, Y3 is N and Y4 is CR9, or
• Y1 is CR6, Y2 is N, Y3 is CR8 and Y4 is CR9, or
• Y1 is CR6, Y2 is CR7, Y3 is N and Y4 is CR9, or
• Y1 is CR6, Y2 is CR7, Y3 is CR8 and Y4 is N;
• R6 is H or alkylamino;
• R7 is alkoxy, dimethylamino, H, methyl, methylamino, OH;
• R8 is cyano, dimethylamino, H, halo;
• R9 is alkoxy, cyclopropyl, haloalkyl dimethylamino, H, halo, alkyl;
• R10 is H or halo;
• Y5 is NR11, Y6 is —C(═O)—, and Y7 is CR13 or N, or
• Y5 is —C(═O)—, Y6 is NR12 and Y7 is CR13;
• R11 is alkyl or H;
• R12 is alkyl or H;
• R13 is H, alkyl or halo;
• R14 is H, alkyl, halo, or haloalkyl;
• Y8 is —CH— or —N—;
• Y9 is —CH— or —N—;
• Y10 is —CH2— or —O—;
• R15 is H, alkyl, or haloalkyl;
• and pharmaceutically acceptable salts thereof.